These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9109532)

  • 41. Binding of [125I]corticotropin releasing factor to blood immunocytes and its reduction in Alzheimer's disease.
    Singh VK; Fudenberg HH
    Immunol Lett; 1988 May; 18(1):5-8. PubMed ID: 2837436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis and pharmacological characterization of new highly selective CRF(2) antagonists: development of 123I-K31440 as a potential SPECT ligand.
    Rühmann A; Chapman J; Higelin J; Butscha B; Dautzenberg FM
    Peptides; 2002 Mar; 23(3):453-60. PubMed ID: 11835994
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cleavage of recombinant human corticotropin-releasing factor (CRF)-binding protein produces a 27-kilodalton fragment capable of binding CRF.
    Woods RJ; Kemp CF; David J; Sumner IG; Lowry PJ
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2788-94. PubMed ID: 10443681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations.
    Bissette G; Reynolds GP; Kilts CD; Widerlöv E; Nemeroff CB
    JAMA; 1985 Dec; 254(21):3067-9. PubMed ID: 3877182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous application of ovine and human corticotropin releasing factor (CRF): ACTH, cortisol and CRF levels.
    Stalla GK; Hartwimmer J; Schopohl J; von Werder K; Müller OA
    Neuroendocrinology; 1986; 42(1):1-5. PubMed ID: 3001563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spinal fluid CRF reduction in Alzheimer's disease.
    Mouradian MM; Farah JM; Mohr E; Fabbrini G; O'Donohue TL; Chase TN
    Neuropeptides; 1986; 8(4):393-400. PubMed ID: 3493444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid agonist-induced phosphorylation of the human CRF receptor, type 1: a potential mechanism for homologous desensitization.
    Hauger RL; Smith RD; Braun S; Dautzenberg FM; Catt KJ
    Biochem Biophys Res Commun; 2000 Feb; 268(2):572-6. PubMed ID: 10679245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2.
    Martínez V; Wang L; Rivier JE; Vale W; Taché Y
    J Pharmacol Exp Ther; 2002 May; 301(2):611-7. PubMed ID: 11961064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Urocortin: slower dissociation than corticotropin releasing factor from the CRF binding protein.
    Henriot S; Dautzenberg FM; Kilpatrick GJ
    Eur J Pharmacol; 1999 Jul; 376(3):321-4. PubMed ID: 10448894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peritoneal fluid levels of immunoreactive corticotropin-releasing factor (CRF) and CRF-binding protein (CRF-BP) in healthy and endometriosic women.
    Florio P; Busacca M; Vignali M; Viganò P; Woods RJ; Lowry PJ; Genazzani AR; Luisi S; Santuz M; Petraglia F
    J Endocrinol Invest; 1998 Jan; 21(1):37-42. PubMed ID: 9633021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of corticotropin-releasing factor-binding protein expression in cultured rat astrocytes.
    Maciejewski D; Crowe PD; De Souza EB; Behan DP
    J Pharmacol Exp Ther; 1996 Aug; 278(2):455-61. PubMed ID: 8768691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal.
    Heinrichs SC; Lapsansky J; Behan DP; Chan RK; Sawchenko PE; Lorang M; Ling N; Vale WW; De Souza EB
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15475-80. PubMed ID: 8986836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.
    Gulyas J; Rivier C; Perrin M; Koerber SC; Sutton S; Corrigan A; Lahrichi SL; Craig AG; Vale W; Rivier J
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10575-9. PubMed ID: 7479843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancement of performance in multiple learning tasks by corticotropin-releasing factor-binding protein ligand inhibitors.
    Heinrichs SC; Vale EA; Lapsansky J; Behan DP; McClure LV; Ling N; De Souza EB; Schulteis G
    Peptides; 1997; 18(5):711-6. PubMed ID: 9213365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating human corticotropin-releasing factor-binding protein levels following cortisol infusions.
    Kasckow JW; Lupien SJ; Behan DP; Welge J; Hauger RJ
    Life Sci; 2001 Jun; 69(2):133-42. PubMed ID: 11441903
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat.
    Spina MG; Merlo-Pich E; Akwa Y; Balducci C; Basso AM; Zorrilla EP; Britton KT; Rivier J; Vale WW; Koob GF
    Psychopharmacology (Berl); 2002 Mar; 160(2):113-21. PubMed ID: 11875628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Corticotropin-releasing factor-binding protein (CRF-BP) inhibits CRF- and urotensin-I-mediated activation of CRF receptor-1 and -2 in common carp.
    Manuel R; Metz JR; Flik G; Vale WW; Huising MO
    Gen Comp Endocrinol; 2014 Jun; 202():69-75. PubMed ID: 24769042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of magnesium sulfate on the placental corticotropin-releasing factor (CRF) and CRF binding protein mRNA expression in perfused human placental cotyledon.
    Kropach N; Holtzman D; Vitner D; Bar J; Chen A; Kovo M
    J Matern Fetal Neonatal Med; 2016; 29(3):376-9. PubMed ID: 25655525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Corticotropin-releasing factor decreases vasogenic brain edema.
    Tjuvajev J; Uehara H; Desai R; Beattie B; Matei C; Zhou Y; Kreek MJ; Koutcher J; Blasberg R
    Cancer Res; 1996 Mar; 56(6):1352-60. PubMed ID: 8640825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Corticotropin-releasing factor type-2 receptor and corticotropin-releasing factor-binding protein coexist in rat ventral tegmental area nerve terminals originated in the lateral hypothalamic area.
    Slater PG; Noches V; Gysling K
    Eur J Neurosci; 2016 Jan; 43(2):220-9. PubMed ID: 26503565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.